Tanaka Yuko, Ikeda Naoya, Niho Seiji, Ishida Kazuyuki
Department of Cancer Genome, Dokkyo Medical University, 880 Kitakobayashi, Shimotsuga District, Mibu, Tochigi 321-0293 Japan.
Department of Pulmonary Medicine and Clinical Immunology, Dokkyo Medical University, 880 Kitakobayashi, Shimotsuga District, Mibu, Tochigi 321-0293 Japan.
Int Cancer Conf J. 2024 Sep 10;13(4):353-359. doi: 10.1007/s13691-024-00723-0. eCollection 2024 Oct.
Trastuzumab deruxtecan (T-DXd), a high-payload antibody drug conjugate, has been reported to exert potent antitumor effects and has recently shown promising efficacy against human epidermal growth factor receptor 2 (HER2)-positive adenocarcinoma. Despite its high efficacy, interstitial lung disease (ILD) is a severe adverse event (AE) associated with T-DXd. This report describes a patient who was successfully treated with a dose-reduced T-DXd challenge after recovery from ILD. Little disease progression was observed during the treatment interruption period; thus, the effect of T-DXd was considered to have been maintained. T-DXd may induce ILD, and re-administration under careful observation is considered an important option for treating patients with HER2-positive breast cancer.
曲妥珠单抗德瓦鲁单抗（T-DXd）是一种高载量抗体药物偶联物，据报道具有强大的抗肿瘤作用，最近在治疗人表皮生长因子受体2（HER2）阳性腺癌方面显示出有前景的疗效。尽管其疗效显著，但间质性肺病（ILD）是与T-DXd相关的严重不良事件（AE）。本报告描述了一名患者，该患者在从ILD康复后成功接受了剂量降低的T-DXd激发治疗。在治疗中断期间观察到疾病进展甚微；因此，认为T-DXd的疗效得以维持。T-DXd可能诱发ILD，在密切观察下重新给药被认为是治疗HER2阳性乳腺癌患者的重要选择。
